Replies to post #168558 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

I doubt it. Their AD drug failed on both primary endpoint in the P3 trial. The data to be presented at CTAD is post hoc mined subgroup data.

The float is very small and insiders prop up the stock by large market purchases.